A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer
Michaela J. Higgins(Cancer Trials Ireland), Vered Stearns(Johns Hopkins University), Leisha A. Emens(Johns Hopkins University), Amanda L. Blackford(Johns Hopkins University), John H. Fetting(Johns Hopkins University), Antonio C. Wolff(Johns Hopkins University), Nancy E. Davidson(WinnMed), Tatiana M. Prowell(United States Food and Drug Administration), James M. Rae(University of Michigan), Mitch Dowsett(Institute of Cancer Research), Celia Byrne(National Cancer Institute), Elizabeth Folkerd(Royal Marsden Hospital), Pendleton P. Powers(Johns Hopkins University), Roger S. Blumenthal(House of Representatives), Deborah K. Armstrong(Johns Hopkins University), Hannah Green(Dana-Farber Cancer Institute), Stacie C. Jeter(Johns Hopkins University), Nagi F. Khouri(Johns Hopkins University), Judy E. Garber(Dana-Farber Cancer Institute), Shannon A. Slater(Parkland Health & Hospital System), Jacklyn N. Thibert(Johns Hopkins University)
Cited by 64
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
|Journal of the American College of Cardiology|2018|2.6k